DNA array analysis of interleukin-2-regulated immediate/early genes
Carol Beadling and Kendall A Smith*

Address: Division of Immunology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
E-mail: Carol Beadling - cbeadlin@med.cornell.edu; Kendall A Smith* - kasmith@med.cornell.edu
*Corresponding author

Abstract

Background: Lymphocyte activation culminates in blastogenesis, cell cycle progression, DNA replication and mitosis. These complex cellular changes are programmed almost simultaneously by multiple ligands and receptors that trigger specific signal transduction pathways and transcription factors. Until now, the discovery of the genes regulated by each ligand/receptor pair has been hampered by the technologies available.

Results: To identify interleukin-2 (IL-2)-responsive genes, human peripheral blood mononuclear cells (PBMC) were pre-activated with anti-CD3, rested, and restimulated with IL-2 for 4 hr. Gene expression was analyzed using Affymetrix U95Av2 oligonucleotide arrays. To determine the most stringent parameters to score a gene as a bona fide IL-2 target, the expression of 19 known IL-2-regulated genes was examined first. All were induced at least 2-fold, with a difference in fluorescent intensity of ≥100 at p < 0.05. An additional 53 unique genes met these criteria. To determine which of these were immediate/early IL-2 targets in T cells, purified T cells were stimulated with IL-2 for 4 hr in the presence of cycloheximide to prevent secondary gene expression. Of the 72 genes identified in PBMCs, 20 were detected as immediate/early IL-2-regulated genes in purified T cells. In addition, 27 unique genes were IL-2-regulated in T cells but not in PBMCs.

Conclusions: For a successful reductionist approach to the analysis of gene expression in lymphocyte activation, it is necessary to examine purified cell populations and immediate/early gene expression regulated by each ligand/receptor pair involved. This approach should allow the discovery of genes regulated by all of the ligand/receptor pairs involved in lymphocyte activation.

Background

In 1960 Nowell first described lymphocyte activation by mitogenic lectins to result in "blastic transformation" and subsequent mitosis, which are complex cellular events that require several days to evolve [1]. More than 40 years later, we have advanced considerably in our understanding of the cellular and molecular events responsible for these phenomena. Now with the genomic revolution, we are poised on a new threshold of discovery, in that it is finally feasible to begin to identify the genes that are responsible for such complicated cellular processes. However, it is now necessary to develop an experimental approach that will rapidly and accurately facilitate the discovery process.
With the description of lymphocyte-derived growth factor activities in the 1960s and 1970s, it was realized that activated lymphocytes secrete soluble factors that are critical for subsequent lymphocyte proliferation [2,3]. Moreover, in 1967 it was demonstrated that monocytes or macrophages serve as necessary accessory cells for the lymphocyte activation process [4]. Then, in the early 1970s several reports indicated that mitogen- or endotoxin-stimulated macrophages release soluble lymphocyte activating factors (LAFs) that also amplify the activation process [5,6]. Accordingly, lymphokines and monokines, which collectively came to be known as cytokines, became prime research subjects for those interested in lymphocyte activation [7,8]. However, it was not until the 1980s that the cell surface and soluble molecules responsible for the complex cellular changes of lymphocyte activation were identified.

With the isolation of the lymphocyte-derived molecule responsible for T cell Growth Factor (TCGF) activity, which came to be known as interleukin 2 (IL-2) [9,10], and discovery of IL-2 receptors (IL-2R) [11], it could be shown that mitogenic lectins and specific antigens triggered an initial activation event, which was analogous to the activation of cell cycle "competence" by serum-stimulated fibroblasts, and resulted in transition from the G0 to the G1 phase of the cell cycle [12,13]. However, just as in serum-stimulated fibroblasts, this initial activation event did not result in lymphocyte proliferation. Instead, it appeared that the initial activation of cellular competence triggered by the mitogenic lectins was amplified by the LAF activity, which became known later as IL-1, and led to the secretion of the lymphocyte-derived IL-2 and the expression of IL-2Rs [14,15]. The subsequent interaction of IL-2 with the IL-2Rs then stimulated blastic transformation and progression through G1 and into the S phase of the cell cycle, followed by mitosis [16]. Furthermore, detailed studies indicated that successful activation of the IL-2R is a quantal (i.e. all-or-none) event that depends on surpassing a threshold of a finite number of IL-2-IL-2R interactions [13,17,18]. This threshold corresponds to surpassing the "restriction (R) point" in the mid to late G1 phase of the cell cycle, first described by Pardee for serum-activated fibroblasts [19]. Accordingly, activation of lymphocyte proliferation was realized to require at least 3 signals, one delivered to the T cell via the lectin, another supplied as a soluble factor by accessory macrophages, and a third contributed by the IL-2R interaction.

With the discovery of the T cell antigen receptor (TCR) in 1983 [20–22] it was possible to demonstrate that the first signal is delivered via antigenic activation of the TCR [12]. Subsequently, discovery of accessory "co-stimulatory" molecule expression by "helper" T cells (Th), revealed that activation solely of the TCR itself was insufficient to fully activate IL-2 gene expression and T cell proliferation. Instead, in the mid '80s it was found that the activation of co-stimulatory molecules like CD28 expressed by T cells via ligands such as B7 expressed by antigen presenting cells (APC), deliver additional signals that synergize with those emanating from the TCR, and result in maximal IL-2 gene transcription [23]. As well, CD28 activation stabilizes IL-2 mRNA transcripts, prolonging IL-2 mRNA life span [24]. Thus, in addition to soluble macrophage-derived products, cell surface molecules expressed by APCs also contribute to the 2nd signal attributed to the APCs.

The molecules responsible for the contribution by the soluble macrophage-derived LAFs still remain obscure, even today. Initially the nomenclature of IL-1 and IL-2 was created to delineate the sequential action of an assumed single macrophage-derived soluble factor (IL-1), which promoted the production of a single lymphocyte-derived factor (IL-2) [14,15,25]. However, the molecular nature of the LAF activity was never fully elucidated, even after the isolation and identification of multiple mitogen/endotoxin-stimulated macrophage-derived products, such as IL-1, IL-6, IL-12, IL-18, and Tumor Necrosis Factor-alpha (TNF-α). It is probable that all of these macrophage-derived soluble factors together make up the activity originally ascribed to LAF. Accordingly, it is obvious that addition of a polyclonal activating ligand such as phytohemagglutinin to peripheral blood mononuclear cells (PBMCs) leads to the activation of soluble macrophage-derived and lymphocyte-derived activating factors, and the almost simultaneous activation of multiple cell surface receptors, signaling pathways and transcription factors that ultimately all contribute to lymphocyte activation.

Stimulation of the various receptors expressed by T cells and APCs results in the activation of distinct and also redundant signal transduction pathways, and in the activation of distinct as well as redundant transcription factors. Accordingly, it has been assumed that triggering any of these receptors should result in the expression of distinct as well as redundant cellular genes. Until recently the identification of large numbers of genes triggered by distinct ligands has been difficult, owing to the cumbersome methods available for gene identification. Cochran and Stiles were among the first to use differential cloning methods to identify PDGF-regulated genes in fibroblasts [26]. These investigators focused on the expression of immediate/early PDGF-stimulated genes, by activating the cells in the presence of inhibitors of protein synthesis such as cycloheximide, thereby preventing the expression of secondary genes.

Subsequently, Zipfel and co-workers employed subtractive hybridization to isolate and differentially clone immediate/early genes activated via the T cell antigen
receptor in the presence of cycloheximide [27]. A total of 60 novel TCR-induced immediate/early genes were isolated, but most were not identified at the time, in that DNA cloning and sequencing methods were tedious and time consuming.

New differential cloning methods were developed subsequently, including differential display [28], sulfhydryl labeling and affinity purification of newly-synthesized transcripts [29], representational difference analysis [30], and serial analysis of gene expression [31]. Each methodological advance has improved both the sensitivity of detection of differentially expressed genes, as well as the speed with which the genes may be identified. However, the development of DNA microarray technology, which allows rapid interrogation of thousands of genes and the detection of gene expression at frequencies even less than 1 in 100,000, has now greatly facilitated such experimentation [32,33]. This communication represents our initial efforts to use DNA microarrays in a reductionist approach to begin to identify the genes expressed as a consequence of triggering each individual ligand during lymphocyte ac-

### Table 1: Composition of PBMCs

| Surface Marker | CD3   | CD14  | CD19  | CD56  |
|----------------|-------|-------|-------|-------|
| Percentage     | 80 ± 2| 0.7 ± 0.3| 7 ± 1 | 8 ± 1 |

Results are averages ± SE from 5 independent experiments

### Table 2: Expression of Known IL-2-Regulated Genes in PBMCs

| Probe Set | Accession Number | Gene Name | Fold Change ± SE | Difference of Means ± SE | P Value |
|-----------|------------------|-----------|------------------|--------------------------|---------|
| HUMGAPDH  | M33197           | GAPDH     | 1.04 ± 0.06      | 110 ± 10                  | NA      |
| HSAC07    | X00351           | Actin     | 1.06 ± 0.01      | 277 ± 7                   | NA      |
| 404_at    | X52425           | IL-4R     | 2.0 ± 0.3        | 327 ± 41                  | 0.00176 |
| 1583_at   | M32215           | TNFR      | 2.1 ± 0.2        | 615 ± 72                  | 0.00050 |
| 1476_s_at | U22376           | c-myb     | 2.2 ± 0.4        | 143 ± 27                  | 0.02090 |
| 1852_at   | X02910           | TNF-α     | 2.5 ± 0.5        | 181 ± 37                  | 0.00597 |
| 1474_s_at | U22376           | c-myb     | 2.5 ± 0.4        | 114 ± 20                  | 0.00848 |
| 34823_at  | X60708           | CD26      | 2.5 ± 0.5        | 131 ± 26                  | 0.01254 |
| 883_s_at  | M54915           | CR7 (pim-1) | 2.9 ± 0.4   | 910 ± 116              | 0.00002 |
| 828_at    | U19487           | CR3 (PGE2-R) | 3.0 ± 0.9     | 137 ± 39                 | 0.02002 |
| 36650_at  | D13639           | cyclin D2  | 3.0 ± 0.4        | 393 ± 55                  | 0.00024 |
| 37014_at  | M33882           | IFN-induced p78 | 3.1 ± 0.5     | 518 ± 86                 | 0.00134 |
| 41592_at  | AB000734         | JAB (SOCS1, SSI-1) | 3.3 ± 0.4   | 368 ± 41              | 0.00001 |
| 36143_at  | U13737           | caspase 3  | 3.4 ± 0.4        | 192 ± 25                  | 0.00003 |
| 39154_at  | AI952982         | CR6 (GADD45γ) | 3.5 ± 0.9    | 178 ± 48                | 0.00633 |
| 2042_s_at | M15024           | c-myb     | 3.5 ± 0.7        | 341 ± 68                  | 0.00169 |
| 40790_at  | AB004066         | CR8 (DEC1, STRA13) | 3.7 ± 0.6    | 762 ± 133             | 0.00021 |
| 1779_s_at | M16750           | CR7 (pim-1) | 3.7 ± 0.5     | 112 ± 163               | 0.00001 |
| 1067_at   | U03858           | bcl2      | 3.7 ± 0.7        | 317 ± 60                  | 0.00425 |
| 36314_at  | U04806           | ft3 ligand | 4.1 ± 0.6     | 374 ± 53                  | 0.00003 |
| 1067_g_at | U03858           | ft3 ligand | 4.9 ± 0.9     | 201 ± 38                  | 0.00014 |
| 258_at    | M16441           | TNF-β     | 6.6 ± 1.7        | 319 ± 83                  | 0.00050 |
| 1702_at   | X01057           | IL-2Rp55  | 7.9 ± 1.6        | 134 ± 26                  | 0.00006 |
| 33945_at  | D31797           | CD40L     | 9.5 ± 3.7        | 131 ± 31                  | 0.00748 |
| 1579_at   | M27288           | Oncostatin M | 16.1 ± 6.0   | 144 ± 54                | 0.01202 |
| 36296_at  | D12614           | TNF-β     | 88.6 ± 36.2      | 881 ± 360                 | 0.00013 |
tivation. Because the IL-2/IL-2R interaction is discrete molecularly, and leads to a very finite, quantal decision to undergo blast transformation, DNA synthesis and mitosis, we have focused our first efforts on identifying IL-2-regulated genes expressed by normal human T cells.

**Results**

**Detection of IL-2-regulated genes in peripheral blood mononuclear cells (PBMCs)**

Responses of PBMCs to IL-2 are complex, involving direct effects of IL-2 on gene expression by T cells, B cells and NK cells, as well as secondary effects mediated by additional cytokines and transcription factors expressed by these cells in response to IL-2. To identify the maximal number of IL-2-regulated genes, PBMCs comprised of ~80% CD3+ lymphocytes, with smaller fractions of monocytes, B cells and NK cells (Table 1) were examined. The cells were pre-activated for 72 hr with anti-CD3 to induce T cell IL-2 receptor expression, then washed and rested for 36–40 hr, prior to restimulation with IL-2 for 4 hr [16].

Five independent experiments were performed with PBMCs from different donors to identify IL-2-regulated genes represented on the Affymetrix U95Av2 oligonucleotide array. A comparison was made between the pre-activated, rested cells, and those restimulated with IL-2 for 4 hr. The expression levels were analyzed using DNA-Chip Analyzer software [34], with normalization to the average chip signal intensity for each experiment, and a 10th percentile value cut-off for ‘absent’ genes. Approximately 45% of the ~12,600 probe sets were detected above background. Using the criterion of p < 0.05 for the difference of means between the two groups, a total of 316 of these ~5,800 probe sets (~5.4%) were identified as putative IL-2-responsive genes. A complete list of all IL-2-responsive genes identified in PBMCs and T cells can be found in the attached file ‘IL-2-regulated genes’.

**Detection of PBMC genes already known to be IL-2-regulated**

The expression patterns of 19 genes already known to be IL-2-regulated, which were represented by 25 distinct probe sets on the array, were used to determine the range of expression parameters that might be most likely to identify bona fide IL-2-regulated genes (Table 2). As negative controls, glyceraldehyde-6-phosphate dehydrogenase (GAPDH) and actin were used as examples of genes that do not change expression levels under the experimental conditions used; their expression levels were indeed constant without or with IL-2 treatment (1.04 ± 0.06 and 1.06 ± 0.01 fold change, respectively). By comparison, the 19 selected genes showed IL-2-induced changes in expression levels, ranging from 2.0 ± 0.3-fold (IL-4R, probe set 404_at) to >80-fold (TNFβ 36296_at). The subtractive differences in fluorescent intensity ranged from 114 ± 20 (c-myb 1474_s_at) to >1000 (CR7 1779_s_at). Four of the genes (c-myb, CR7, flt3 ligand, TNF-β) were detected with more than one probe set, and these replicates were in fairly good agreement. It is worthy of note that there is not a correlation between the subtracted difference and the fold change in gene expression levels. This is likely due to the fact that there is a wide range in the abundance classes of RNA transcripts derived from different genes, from as few as 1 copy per cell to several thousand copies per cell [35].

The signal intensity of a particular transcript detected on an oligonucleotide array would thus be directly related to this abundance level. Therefore, the subtracted change in signal intensity would be profoundly affected by the absolute number of cellular copies of a given transcript. By comparison, the fold induction is independent of absolute transcript copy number.

**Detection of additional IL-2-responsive PBMC genes**

Based on the results obtained with known IL-2 target genes, the criteria used to identify additional bona fide IL-2-regulated genes in these samples were set at ≥ 2-fold change, with a subtracted difference in fluorescent intensity ≥ 100, and a significance level of the difference between the means of the two treatment groups of p < 0.05. Of the 316 probe sets that met the standard of p < 0.05, 251 (79%) also met the additional criteria of either fold change ≥ 2, or subtracted difference ≥ 100, while only 84 probe sets (27%) met all three criteria.

These 84 probe sets represent 72 unique genes (60 IL-2-induced genes and 12 IL-2-repressed genes) that can be segregated into 8 functional groups. Figure 1 shows the fold induction and subtracted differences in expression levels of these probe sets. Among the 4 apoptosis-regulating genes, bcl2, caspase 3 and DRAK2 are all induced by IL-2, while the expression of Toso is suppressed. It is noteworthy that the IL-2 induction of bcl2 would be expected to promote cellular survival, while the IL-2 regulation of the other three genes would be expected to promote apoptosis. Additional IL-2-responsive genes include those encoding 6 cell surface proteins, 11 cytokine and chemokine receptors, as well as 15 signal transduction mediators, 6 genes involved in cellular metabolism and biosynthesis, 3 cell cycle regulators and 12 transcription factors. IL-2-suppressed genes include lymphocyte antigen 9, inositol 1,4,5-trisphosphate 3-kinase B, and cdc25B, as well as transcriptional regulators MAX-interacting protein 1, CBP/p300-interacting transactivator, inhibitor of DNA binding 3 (Id3), glucocorticoid-induced leucine zipper (GILZ), and zinc finger protein 36/ERF-2. All of the 19 already known IL-2-regulated genes (Table 2) were also identified in this 72-gene cohort, thereby yielding 53 newly identified IL-2-regulated genes expressed by PBMCs after 4 hours of IL-2 stimulation.
**Figure 1**

**IL-2-regulated genes in PBMCs.** Pre-activated, rested human PBMCs were left untreated or restimulated for 4 hr with IL-2, and RNA probes were prepared for hybridization with Affymetrix U95Av2 arrays. A total of 84 probe sets were identified that showed fold change $\geq 2$ (columns, left axis), subtracted difference $\geq 100$ (diamonds, right axis), and a significance value of the difference between the means of $p < 0.05$. The probe sets represent 72 unique genes, and can be segregated into 8 functional groups.
**IL-2-regulated immediate/early genes in T cells**

The PBMC populations used in our initial experiments included NK cells, monocytes and B cells, as well as T cells. In addition, cytokines including TNFα, TNFβ and flt3 ligand were induced by IL-2 as detected by the arrays, so that the IL-2 effects could be mediated by the action of these intermediary cytokines on other cells in the mixed population, or as well, by the 12 transcriptional targets activated by IL-2. Therefore to identify the direct IL-2 targets in T cells, we used CD56-depleted, CD2-selected T cells, which were 94 ± 1% CD3+ cells. The PBMCs were pre-activated with anti-CD3 for 72 hr, the T cells purified, and rested for 36–40 hr prior to restimulation for 4 hr with 1 nM IL-2. In addition, 10 µg/mL cycloheximide (CHX) was included to block protein synthesis, so that only immediate/early IL-2-regulated genes were detected. CHX has been shown to both elevate and prolong the expression of many transiently induced transcripts [26,29], so that the 4 hr IL-2 stimulation in the presence of CHX should enable detection of genes induced within minutes as well as hours. Samples from 4 independent experiments with pre-activated, rested cells, or cells treated with CHX alone were combined for data analysis, and compared to cells treated with IL-2 ± CHX.

As depicted in Figure 2A, using only the criterion of significance level of \( p < 0.05 \) for the difference between the means of the two groups, 449 probe sets were identified as IL-2-regulated immediate-early targets in the pure T cells. Of these probe sets, 110 were also detected in the IL-2-stimulated PBMCs. As shown in Figure 2B, when a second standard was included, either a fold change ≥ 2, or a subtracted difference ≥ 100, 161 probe sets (36%) were expressed as immediately/early genes in purified T cells, and of these, 71 were also IL-2-regulated in PBMCs. However, when all 3 criteria were applied (Figure 2C), a total of only 52 probe sets (12%) were found to be immediate/early, IL-2-regulated genes in T cells. Twenty-three of these 52 probe sets were among the 84 probe sets identified previously as meeting all 3 criteria in the experiments with PBMCs (Figure 3). By comparison, the control genes actin and GAPDH showed 1.1 ± 0.1 and 1.3 ± 0.2-fold change, respectively.

The 23 probe sets represent 20 IL-2-regulated immediate/early genes. Therefore, only ~1/3 of the genes discovered to be IL-2-regulated in PBMCs are actually immediate/early direct IL-2 targets in T cells. These direct IL-2 immediate/early target genes included 4 genes that were suppressed, DSIP/GILZ, the zinc finger protein 36/ERF-2/Tis11d, Toso, and cdc25B. Notably, of the 16 IL-2-induced genes, we had already been identified 4 previously as IL-2 targets using differential colony hybridization (CR3, CR6, CR7, CR8) [29], while the 3 other known IL-2 stimulated target genes included TNFβ, the IL-4R, and the anti-apoptotic gene, Bcl2. Thus, only 9 genes were newly identified as IL-2-induced immediate/early T cell genes; including the signaling proteins SLP76 and RGS1, the transcription factors IRF4 and XBP1, and 5 miscellaneous genes (DKFZp586F1323, mitofilin, CAMP-specific phosphodiesterase 4B, CMP-N-acetylneuraminic monooxygenase, and the aryl hydrocarbon receptor).
Figure 3
IL-2-regulated genes in PBMCs and purified T cells. A total of 23 probe sets met all three expression criteria of fold change ≥ 2 (columns, left axis), subtracted difference ≥ 100 (diamonds and circles, right axis), and p < 0.05 in both PBMCs and purified T cells. These probe sets represent 20 unique genes.
In addition to the 23 probe sets in common with those identified in PBMCs, 29 others were detected as IL-2-regulated immediate/early targets in the purified T cells (Figure 2C). These probe sets met all three of the criteria of ≥2-fold change, subtracted difference ≥100, and p < 0.05 in T cells, but were not IL-2-regulated in PBMCs. These probe sets represent 27 unique genes, and are presented in Figure 4. Notably, only three of these were induced, while the remaining 24 were all suppressed in response to IL-2 + CHX.

Of the remaining 61 probe sets identified in PBMCs (Figure 2C), 31 showed changes in expression levels in T cells with p < 0.05, although either the fold change was less than 2.0, or the magnitude of the change was less than 100 (Table 3). These 31 probe sets are derived from 27 unique genes, and most likely represent bona fide IL-2 targets, since the group includes the genes JAB/SSI-1/SOCS-1, flt3 ligand, IL-2Rp55, caspase 3, and p78, which have already been reported as IL-2-induced genes. If these genes are also included, 47 of the 72 unique genes (65%) identified in PBMCs are IL-2-regulated immediate/early genes in pure T cells.

Similarly, of the 29 probe sets identified as meeting all 3 criteria only in pure T cells, 7 showed differences in expression with p < 0.05 in PBMCs (Table 4). These include linker for activation of T cells, T-cell-specific transcription factor 7, STAT4, IL-7R, PAS ser/thr kinase, I-mfa domain-containing protein, and an unknown gene designated DKFZp586D1122. Notably, all of the other genes (22) were suppressed by IL-2 in the PBMCs, as they were in the T cells, although they did not meet the significance value of p < 0.05 in the PBMCs.

**Discussion**

Lymphocyte activation is initiated by specific antigen/receptor interactions, and aided by accessory molecules. However, subsequently, cytokine and cytokine receptor expression ensues, and the cytokines ultimately drive the clonal expansion and functional differentiation of the antigen-selected lymphocyte populations. IL-2 was initially identified by virtue of its T cell growth factor activity, and IL-2 is now recognized as the pivotal cytokine in promoting mature peripheral T cell proliferation [36,37]. Therefore, to initiate the identification of the genes responsible for lymphocyte activation, we chose first to delineate the genetic mechanisms of IL-2 action. Using oligonucleotide arrays of known genes to identify IL-2-regulated genes in human lymphocytes, a total of 72 unique genes were found to change expression within 4 hr of IL-2 stimulation of PBMCs. These genes could be segregated into functional groups, including cell surface proteins, cytokine and chemokine receptors, as well as signal transduction mediators, cytokines, genes involved in cellular metabolism and biosynthesis, cell cycle regulators and transcription factors.

In order to define the criteria that we used to sort the microarray data in this series of experiments, we were able to take advantage of previous reports of 19 known IL-2-regulated genes. By assessing the characteristics of the changes in expression of these known IL-2 targets, we were able to define a range of both fold-induction and subtracted difference that encompassed all of these genes. When applied to the total data set, these criteria were likely to identify additional meaningful IL-2-regulated genes. Since 19 of these genes had already been reported to be IL-2-induced genes, our DNA array experiments identified 53 additional IL-2-regulated genes expressed by PBMCs. However, only 20 of these genes were found to be IL-2-regulated immediate/early T cell genes.

It is important to discriminate these results from other analyses of T cell activation that have employed antigen receptor activation, as opposed to IL-2. The TCR and IL-2 receptors activate some shared signaling pathways, such as the Ras-Raf-MAP kinase and PI-3-kinase pathways [38]. However, there are differences, such as the Jak-Stat pathway, which is unique to the cytokines [39], and the Ca++/Calcineurin pathway, which is activated by the TCR. These signaling pathways culminate in the activation of specific transcription factors, so that there must be both shared target genes, as well as genes unique to antigen or IL-2 signaling. As TCR signaling induces the expression of IL-2, as well as other cytokines and their receptors, the ultimate T cell response is an amalgam of both antigen- and cytokine receptor-triggered events.

This point is well illustrated by the report of Teague et al [40], who used microarrays to identify murine T cell genes induced in vivo by SEB stimulation after 8 and 48 hours. Again, cytokine and cytokine receptor genes were induced during these time intervals, so that the entire spectrum of genes identified included both antigen- and accessory molecule-activated, as well as cytokine-regulated targets. Similarly, Ellisen et al [41] used DNA arrays to monitor ConA-induced genes in human T lymphocytes, over a time scale ranging from 4 to 48 hours. Inducible genes included IL-2 and TNF-α, as well as the IL-1R, IL-2Ra and IL-4R. Thus, at the time points used in this study, many of the genes detected were likely regulated by these cytokines as well as Con A. In a similar vein, Herblot et al [42] used a subtractive approach to identify 66 genes induced by IL-2 but not IL-4 in a murine T cell line. They further demonstrated that while in vitro, ConA could induce expression of the IL-2 target genes in T cells from IL-2 +/- mice, the genes were not induced by ConA treatment of T cells from IL-2-/- mice. Thus, ConA induces IL-2 and IL-2R expression, and the cytokine drives expression of additional spe-
Figure 4
**IL-2-responsive genes in purified T cells.** A total of 29 additional probe sets met all three expression criteria of fold change ≥ 2 (columns, left axis), subtracted difference ≥ 100 (diamonds and circles, right axis), and p < 0.05 in purified T cells, but did not meet all three criteria in PBMCs. These probe sets represent 27 unique genes.
Table 3: T cell expression levels of genes identified in PBMCs

| Probe Set | Accession Number | Gene Name                  | Fold ± SE | Difference ± SE | P Value |
|-----------|------------------|----------------------------|-----------|-----------------|---------|
| 38518_at  | Y18004           | SCML2                      | 1.4       | 158 ± 13        | 0.00214 |
| 2042_s_at | M15024           | c-myb                      | 1.9       | 67 ± 16         | 0.00388 |
| 33490_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 14         | 0.00141 |
| 39072_at  | L07648           | MAX-IP                     | 1.7       | 158 ± 13        | 0.00214 |
| 1715_at   | U37518           | TRAIL                      | 1.5       | 67 ± 16         | 0.00078 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 14         | 0.00141 |
| 39936_at  | U95627           | p78                        | 1.5       | 66 ± 7          | 0.01611 |
| 33812_at  | AL049415         | Meltrin                    | 1.8       | 104 ± 10        | 0.00286 |
| 41592_at  | AB000734         | JAB (SSI-1, SOCS1)         | 8.1       | 265 ± 37        | 0.01560 |
| 39362_at  | U95627           | CCR2                       | 5.1       | 96 ± 14         | 0.02283 |
| 37565_at  | X85750           | mono to mac diff           | 2.0       | 36 ± 4          | 0.00735 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 11         | 0.00899 |
| 1674_at   | U13990           | c-myb                      | 1.8       | 33 ± 4          | 0.00988 |
| 36134_at  | U13990           | Caspase 3                  | 2.5       | 67 ± 14         | 0.01269 |
| 37565_at  | X85750           | mono to mac diff           | 2.0       | 36 ± 4          | 0.00735 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 11         | 0.00899 |
| 1674_at   | U13990           | c-myb                      | 1.8       | 33 ± 4          | 0.00988 |
| 36134_at  | U13990           | Caspase 3                  | 2.5       | 67 ± 14         | 0.01269 |
| 37565_at  | X85750           | mono to mac diff           | 2.0       | 36 ± 4          | 0.00735 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 11         | 0.00899 |
| 1674_at   | U13990           | c-myb                      | 1.8       | 33 ± 4          | 0.00988 |
| 36134_at  | U13990           | Caspase 3                  | 2.5       | 67 ± 14         | 0.01269 |
| 37565_at  | X85750           | mono to mac diff           | 2.0       | 36 ± 4          | 0.00735 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 11         | 0.00899 |
| 1674_at   | U13990           | c-myb                      | 1.8       | 33 ± 4          | 0.00988 |
| 36134_at  | U13990           | Caspase 3                  | 2.5       | 67 ± 14         | 0.01269 |
| 37565_at  | X85750           | mono to mac diff           | 2.0       | 36 ± 4          | 0.00735 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 11         | 0.00899 |
| 1715_at   | U37518           | TRAIL                      | 1.5       | 67 ± 16         | 0.00078 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 14         | 0.00141 |
| 39072_at  | L07648           | MAX-IP                     | 1.2       | 158 ± 13        | 0.00214 |
| 1715_at   | U37518           | TRAIL                      | 1.5       | 67 ± 16         | 0.00078 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 14         | 0.00141 |
| 39072_at  | L07648           | MAX-IP                     | 1.2       | 158 ± 13        | 0.00214 |
| 1715_at   | U37518           | TRAIL                      | 1.5       | 67 ± 16         | 0.00078 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 14         | 0.00141 |
| 39072_at  | L07648           | MAX-IP                     | 1.2       | 158 ± 13        | 0.00214 |
| 1715_at   | U37518           | TRAIL                      | 1.5       | 67 ± 16         | 0.00078 |
| 36334_at  | L27071           | TXK kinase                 | 1.7       | 97 ± 14         | 0.00141 |
specific target genes. Recently, Riley et al [43] and Diehn et al [44] described genes regulated by the TCR and the costimulatory receptors CD28, ICOS and CTLA-4, over a time course of 1–48 hours. Once again, numerous cytokines, including IL-2, are strongly induced within 2 hr, such that a number of the observed regulated genes are likely cytokine-responsive targets. Finally, Gonzalez et al [45] have described murine genes induced after 8 hr IL-2 stimulation, which likely include direct targets of IL-2, as well as genes induced via IL-2-regulated cytokines.

Therefore, to discriminate between the distinct genes induced by each ligand that contributes to the overall response initiated by antigenic stimulation, it is important to use cycloheximide to identify immediate/early genes regulated by the TCR and costimulatory receptors vs. IL-2. In addition, the genes activated by TCR, costimulatory receptors and IL-2 must be distinguished from those activated by IL-1, IL-6, IL-12, and TNF-α, as well as the genes regulated by the Toll-like receptors (TLR), all of which have been identified as mediators of lymphocyte activation events that were previously ascribed to LAF. Moreover, as IL-2 itself induces the expression of numerous cytokines and receptors, it is important to discriminate the direct IL-2 targets from those induced secondarily through these intermediaries. Thus, it is worthy of re-emphasis that of the 72 genes regulated by IL-2 in PBMCs, only 20 were found to be bona fide IL-2-regulated immediate/early genes in purified T cells.

In addition to imparting positive activating signals that result in cell cycle progression, IL-2 has also been found to promote negative feedback phenomena. Thus, it is especially intriguing that IL-2 suppresses the expression of many genes, both among PBMCs in the absence of CHX, as well as in purified T cells in the presence of CHX. The suppression of the expression of these genes may well be important in mediating the feedback down-regulatory phenomena.

The high-affinity IL-2 receptor is comprised of three subunits, α, β and γ [46,47]. The α chain is specific to IL-2, while the γ chain is shared among IL-4, IL-7, IL-9, IL-15 and IL-21 [48]. The β chain of the IL-2R is also a component of the IL-15 receptor, in conjunction with a specific IL-15R α chain [49]. The sharing of these receptors by multiple cytokines raises the question of how the ligands can trigger specific responses in the target cells. Several signaling events, including the activation of Jak kinases 1 and 3 are shared among the ‘common γ chain’ cytokines [50]. Other signaling events, such as the activation of Shc, Gab2, SHP-2 and MAPK, are shared among IL-2 and 15, but not the other common γ chain cytokine receptors, and Tyr 388 of IL-2Rβ appears critical for these events [51]. Despite these signaling similarities, it is clear that the biological properties of IL-2 are unique among the common γ chain cytokines, as the other cytokines cannot compensate for IL-2 in the IL-2 knockout mouse [52]. In addition, IL-15 appears uniquely critical for the development of NK cells, as evidenced by the phenotypes of IL-15 [53] and IL-15R α [54] deficient mice. Thus, there must be a means whereby IL-2 and IL-15, as well as the other common γ chain cytokines, trigger distinct intracellular signaling pathways, and target genes. Therefore, identification of each of the cytokine-specific target genes should shed light on the issue of specificity amongst the common γ chain cytokines.

Complete classification of the genes expressed as a consequence of distinct ligand/receptor interactions during lymphocyte activation will also provide a powerful tool for the assessment and treatment of immunological disorders [55]. In addition to defining the target genes of specific cytokines and cell surface ligands, it is possible to further subdivide the genes based on the specific signaling proteins and transcription factors that govern their expression. For example, through the use of STAT5−/− mice, Ihle et al have been able to identify those IL-2 target genes that require STAT5 [56,57]. Similar approaches with mutant signaling proteins, knockouts, or over-expression systems enable such dissection of the signal transduction path-

---

Table 3: T cell expression levels of genes identified in PBMCs (Continued)

| Gene Entrez ID | Gene Symbol | Gene Name | Fold Change |
|---------------|-------------|-----------|-------------|
| 1600_at       | L27071      | TXK kinase| 1.3 ± 0.3   |
| 1852_at       | X02910      | TNF-α     | 1.3 ± 0.2   |
| 39604_at      | AF068836    | cytokeratin BP | 1.3 ± 0.2 |
| 36979_at      | M20681      | Glut3     | 1.2 ± 0.1   |
| 33513_at      | U33017      | SLAM      | 1.3 ± 0.2   |
| 1579_at       | M27288      | Oncostatin M | 1.4 ± 0.3  |
| 41447_at      | AB023207    | chondroitin synthase | 1.3 ± 0.2 |
| 41048_at      | D90070      | APR       | 1.4 ± 0.4   |
| 38618_at      | AC002073    | LIM domain kinase 2 | -1.0 ± 0.1 |

Page 11 of 14
ways leading to specific target genes. Thus, each ligand/receptor pair will ultimately be linked to a specific signature of target genes, derived from the signaling pathways and transcription factors activated. Such information will be invaluable in the diagnosis and treatment of disorders involving aberrancies in these pathways.

**Conclusions**

The rapidity with which lymphocyte activation genes may now be identified using the methods described in this report opens the way to a molecular genetic definition of the immune response, based upon the categorization of the genes regulated by distinct ligand receptor pairs. Consequently, more precise genetic and molecular diagnoses of immune disorders will soon become available, and hopefully, new treatment regimes may be developed to target the specific molecular nature of each disease.

**Materials and Methods**

**Cell culture**

Human peripheral blood mononuclear cells (PBMC) were purified from venous blood of healthy donors by density centrifugation over Histopaque 1.077 (Sigma). Cells were cultured in RPMI1640, 10%FCS, at a density of $1 \times 10^6$ cells/ml, and activated with anti-CD3 (OKT3, 1:500; Ortho Diagnostics). After 72 hr activation, PBMC were washed and replaced in culture without stimulation for 36–40 hr prior to restimulation with 1 nM IL-2 [16].

To purify T lymphocytes, 72 hr OKT3-activated PBMC were depleted of CD56, and positively selected for CD2, using antibody-conjugated magnetic beads (anti-CD56 Polysciences Inc, anti-CD2 Dynal) according to manufacturer's instructions. Subsequent to purification, T cells were replaced in culture for 36–40 hr prior to restimulation with 1 nM IL-2, and/or 10 µg/ml cycloheximide. Cell populations were stained with anti-CD3-APC, CD14-FITC, CD19-PerCP and CD56-PE (Becton Dickinson),

| Probe Set | Accession Number | Gene Name                                           | Fold Change ± SE | Subtracted Difference ± SE | P value         |
|-----------|------------------|-----------------------------------------------------|------------------|---------------------------|----------------|
| 40688_at  | AJ23280          | linker for activation of T cells                    | -1.5 ± 0.1       | -392 ± 37                 | 0.00839        |
| 32649_at  | X59871           | T cell transcription factor 7                       | -1.9 ± 0.3       | -701 ± 116                | 0.00122        |
| 39582_at  | AL050166         | cDNA DKFZp586D1122                                  | 1.9 ± 0.2        | 190 ± 23                  | 0.01324        |
| 3017_at   | L78440           | STAT4                                               | 1.9 ± 0.3        | 328 ± 49                  | 0.01443        |
| 1370_at   | M29696           | interleukin 7 receptor                              | -1.9 ± 0.3       | -590 ± 100                | 0.02437        |
| 40652_at  | D50925           | PAS-serine/threonine kinase                         | -1.8 ± 0.3       | -122 ± 20                 | 0.02458        |
| 37842_at  | AF054589         | 3-mfa domain-containing protein                     | 1.7 ± 0.3        | 175 ± 26                  | 0.03071        |
| 38578_at  | M63928           | CD27                                                | -1.7 ± 0.3       | -511 ± 94                 | 0.07047        |
| 36537_at  | AB011093         | Rho exchange factor p114                            | -1.5 ± 0.3       | -182 ± 30                 | 0.09182        |
| 39248_at  | NJ74607          | aquaporin 3                                         | -1.4 ± 0.2       | -294 ± 37                 | 0.10737        |
| 40191_s_at| AI761647         | IMAGE-2370113                                       | -1.7 ± 0.4       | -96 ± 22                  | 0.11102        |
| 33120_at  | AF045229         | RGS10                                               | -2.9 ± 0.8       | -80 ± 21                  | 0.11973        |
| 33847_s_at| AI304854         | p27 (KIP1)                                          | -1.7 ± 0.4       | -122 ± 27                 | 0.12566        |
| 41656_at  | AF043325         | N-myrriostyltransferase 2                            | -2.1 ± 0.7       | -133 ± 42                 | 0.12988        |
| 38411_at  | U90916           | Human clone 23815                                   | -1.5 ± 0.3       | -195 ± 38                 | 0.14106        |
| 34210_at  | N90866           | CDV52 antigen (CAMPATH-1)                           | -1.6 ± 0.3       | -363 ± 77                 | 0.14541        |
| 245_at    | M25280           | selectin L (adhesion molecule 1)                    | -1.4 ± 0.2       | -329 ± 51                 | 0.17178        |
| 36227_at  | AF043129         | Rho exchange factor p114                            | -1.4 ± 0.3       | -419 ± 76                 | 0.19511        |
| 32140_at  | Y08110           | sortilin-related receptor                           | -1.4 ± 0.3       | -340 ± 67                 | 0.23205        |
| 41819_at  | AF001862         | FYN binding protein (FYB-120/130)                   | -1.4 ± 0.3       | -150 ± 31                 | 0.29859        |
| 40155_at  | D31883           | actin binding LIM protein 1                         | -1.2 ± 0.2       | -100 ± 17                 | 0.36274        |
| 36155_at  | D87465           | KIAA0275 gene product                               | -1.1 ± 0.1       | -211 ± 24                 | 0.41456        |
| 1405_s_at | M21112           | small inducible cytokine A5 (RANTES)                | -1.2 ± 0.2       | -206 ± 27                 | 0.43778        |
| 39330_s_at| M95178           | actin, alpha 1                                      | -1.3 ± 0.3       | -72 ± 16                  | 0.44549        |
| 40813_at  | AI768188         | IMAGE-2371583                                       | -1.2 ± 0.2       | -27 ± 5                   | 0.56999        |
| 1403_s_at | M21112           | small inducible cytokine A5 (RANTES)                | -1.1 ± 0.1       | -196 ± 23                 | 0.63077        |
| 39081_at  | AI547258         | metallothionein 2A                                  | -1.1 ± 0.1       | -2 ± 0                    | 0.70952        |
| 33267_at  | AF035315         | Cluster Incl. AF035315                               | -1.1 ± 0.3       | -43 ± 11                  | 0.75307        |
| 39329_at  | X15804           | actin, alpha 1                                      | -1.1 ± 0.2       | -35 ± 8                   | 0.83226        |
and quantitated by flow cytometry (FacsCalibur, Becton Dickinson).

**Microarray analysis**

Five independent experiments were performed with PBMCs from different donors, and four independent experiments were carried out with purified T cells. Protocols for sample preparation and array hybridization are from Affymetrix. Briefly, total cellular RNA was prepared with Qiagen RNeasy reagents, and 5 µg samples were used to prepare T7-dT-primed double-stranded cDNA (SuperScript Choice, Invitrogen). Biotin-labeled cRNA was prepared by in vitro transcription (BioArray High-Yield T7, Enzo), and hybridization cocktails were prepared with 20 µg cRNA per sample. Hybridization, wash, and staining of Affymetrix human U95Av2 arrays were performed following manufacturer's instructions.

Data analysis was performed with DNA-CHIP Analyzer software [34,58]. Gene expression values were normalized to the average chip signal intensity for each experiment, and a 10th percentile value cut-off was used for ‘absent’ genes that did not give signals significantly greater than background. To calculate IL-2-induced gene expression changes, the subtracted difference values were determined by subtracting the signal intensity of untreated samples from the values of IL-2-treated samples. The fold difference was calculated as (IL-2-treated)/(untreated). Standard errors were derived from 5 independent PBMC experiments, and 4 experiments with purified T cells. The average of the standard errors relative to the mean expression values (SE/mean signal intensity)*100% was 22% for untreated and 15% for IL-2-stimulated PBMCs, and 16% and 19% for the unstimulated and IL-2-treated purified T cell samples, respectively. The p-values were determined by testing whether the absolute difference between treatment group means is not zero by unpaired t-test.

**Competing interests**

None declared.

**Authors’ contributions**

The results reported here represent almost 20 years of effort. K.A.S. initiated the search for IL-2-regulated genes in 1983, using subtractive hybridization, and reported the first IL-2-regulated gene in 1986 [16]. C.B. extended these initial efforts and reported on the identification of 8 immediate/early IL-2-induced genes in 1993 [33]. C.B. conceived and performed the experiments contained in this report, and wrote the manuscript. K.A.S. provided advice in experimental design and analysis of the results, and contributed to the revisions of the manuscript that eventually resulted in the final version.

**Additional material**

- **Additional File 1**
  IL-2 target genes in human PBMCs and T cells [This file contains expression data for IL-2-regulated probe sets detected on the Affymetrix U95Av2 array, using samples prepared from human PBMCs and purified T cells. Click here for file [http://www.biomedcentral.com/content/full/1476-9433-1-2-S1.xls]]

**Acknowledgments**

This work was supported by National Institutes of Health NIAID grants RO1 AI 32031-24 and RO1 AI 44207-02.

**References**

1. Nowell P: Phthoheagglutinin: An initiator of mitosis in cultures of normal human leukocytes. *Cancer Res* 1960, 20:462-466
2. Kasakura S, Lowenstein L: A factor stimulating DNA synthesis derived from the medium of leukocyte cultures. *Nature* 1965, 208:794-796
3. Gordon J, MacLean LD: A lymphocyte-stimulating factor produced in vitro. *Nature* 1965, 208:795-796
4. Moser DE: A requirement for two cell types for antibody formation in vitro. *Science* 1967, 158:1573-1575
5. Bach F, Alter B, Soliday S, Zoschke D, Janis M: Lymphocyte reactivity in vitro II. Soluble reconstituting factor permitting response of purified lymphocytes. *Cell Immunol* 1970, 1:119-227
6. Hoffman M, Dutton R: Immune response restoration with macrophage culture supernatants. *Science* 1971, 172:1047-1048
7. Gery I, Gershon RK, Waksman BH: Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. *J Exp Med* 1972, 136:128-142
8. Gery I, Waksman BH: Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). *J Exp Med* 1972, 136:143-155
9. Robb RJ, Smith KA: Heterogeneity of human T-cell growth factor(s) due to variable glycosylation. *Mol Immunol* 1981, 18:1087-1094
10. Smith KA, Favata MF, Orozslan S: Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. *J Immunol* 1983, 131:1808-1815
11. Robb RJ, Smith KA: Heterogeneity of human T-cell growth factor(s) due to variable glycosylation. *Mol Immunol* 1981, 18:1087-1094
12. Smith KA, Favata MF, Orozslan S: Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. *J Immunol* 1983, 131:1808-1815
13. Robb RJ, Munkch A, Smith KA: T-cell growth factor receptors: Quantitation, specificity, and biological relevance. *J Exp Med* 1981, 154:1455-1474
14. Mueer SC, Hussey RE, Cantrell DA, Hodgdon JC, Schlossman SF, Smith KA, Reinherz EL: Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. *Proc Natl Acad Sci USA* 1984, 81:1509-1513
15. Cantrell DA, Smith KA: The interleukin-2-T-cell system: A new cell growth model. *Science* 1984, 224:1312-1316
16. Smith KA, Lachman LB, Oppenheim JJ, Favata MF: The functional relationship of the interleukins. *J Exp Med* 1980, 151:1551-1556
17. Smith KA, Gilbride KJ, Favata MF: Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells. *Nature* 1980, 287:853-855
18. Stern J, Smith KA: Interleukin-2 induction of T-cell G1 progression and c-myb expression. *Science* 1986, 233:203-206
19. Smith KA: The determinants of T-cell growth. In: *Mediators in Cell Growth and Differentiation* (Edited by: Ford RJ, Maleil AJ). 1985, 185-192
20. Smith KA: Cell growth signal transduction is quantal. *Ann NY Acad Sci* 1995, 766:263-271
21. Pardee AB: A restriction point for control of normal animal cell proliferation. *Proc Natl Acad Sci USA* 1974, 71:1286-1290
22. Mueer SC, Fitzgerald KA, Hussey RE, Hodgdon JC, Schlossman SF, Reinherz EL: Clonotypic structures involved in antigen-specific
human T cell function. Relationship to the T3 molecular complex. J Exp Med 1983, 157:705-719
21. Haskins K, Kubo R, White J, Pigeon M, Kappler J, Marrack P. The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. J Exp Med 1983, 157:1149-1169
22. Hedrick SMCD, Nielsen EA, Davis MM: Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 1984, 308:149-153
23. Verweij CL, Geerts M, Aarden LA: The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987, 166:1055-1069
24. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB: Reversal of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989, 244:339-343
25. Letter to the Editor. Revised nomenclature for antigen-non-specific T cell proliferation and helper factors. J Immunol 1979, 123:2928-2929
26. Cochran BH, Reffel AC, Stiles CD: Molecular cloning of gene sequences regulated by platelet-derived growth factor. Cell 1983, 33:939-947
27. Nef NF, Irving SG, Kelly K, Siebenlist U: Complexity of the primary genetic response to mitogenic activation of human T cells. Mol Cell Biol 1989, 9:1041-1048
28. Liang P, Pardee AB: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992, 257:967-971
29. Beadling C, Johnson K, Smith KA: Isolation of interleukin 2-induced immediate-early genes. Proc Natl Acad Sci USA 1993, 90:2719-2723
30. Hubank M, Schatz DG: Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 1994, 22:5640-5648
31. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. Science 1995, 270:484-487
32. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis RW: Parallel human genome analysis: Microarray-based monitoring of 10000 genes. Proc Natl Acad Sci USA 1996, 93:10614-10619
33. Liphultz RJ, Fodor SP, Gingeras TR, Lockhart DJ: High density synthetic oligonucleotide arrays. Nat Genet 1999, 21(1 Suppl):2-20.
34. Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001, 98:315-316
35. Hastie ND, Bishop J: The expression of three abundance classes of messenger RNA in mouse tissues. Cell 1976, 9:761-764
36. Smith KA: Interleukin 2: Inception, impact and implications. Science 1988, 240:1169-1176
37. Smith KA, Beadling C, Jacobson E: Interleukin 2. In: In Inflammation: Basic Principles and Clinical Correlates. (Edited by: Gallin J, Snyderman R) Lippincott Williams & Wilkins 1999, 463-470
38. Cantrell DA: T cell antigen receptor signal transduction pathways. Annu Rev Immunol. 1996, 14:259-274
39. Ihle JN, Thierfelder W, Teglund S, Stravapodis D, Wang D, Feng J, Parganas E. Signaling by the cytokine receptor superfamily. Ann NY Acad Sci 1998, 865:1-9
40. Teague KT, Hildeman D, Kedil RM, Mitchell T, Rees W, Schaefer BC, Bender J, Kappler J, Marrack P. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc Natl Acad Sci USA 1999, 96:12691-12696
41. Ellisen LW, Palmer RE, Malg RI, Truong VB, Tamayo P, Oliner JD, Haber DA: Cascades of transcriptional induction during human lymphocyte activation. Eur J Cell Biol 2001, 80:321-328
42. Herblot S, Chazagne P, Samady L, Moreau J-L, Demaion C, Froussard P, Liu X, Bonnet J, Thieze T: IL-2-dependent expression of genes involved in cytokine receptor, oncogene regulation and transcriptional control. J Immunol 1999, 162:3280-3286
43. Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavel G, Gregson BP, June CH, Linsey P. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS and CTLA-4 receptors. Proc Natl Acad Sci USA 2002, 99:11790-11795
44. Diehn M, Alizadeh AA, Rando OJ, Liu CL, Stankunas K, Bosstein D, Crabtree GR, Brown P: Genomic expression programs and the
integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci USA 2002, 99:11796-11801
45. Stagg JC, Jordan T, Gobbi G, Pryszwowski MB: Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. Blood Cells, Molecules, and Diseases 2001, 27:572-585
46. Wang HM, Smith KA: The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987, 166:1055-1069
47. Smith KA: The interleukin 2 receptor. Annu Rev Cell Biol 1989, 5:397-425
48. Olosz F, Malek TR: Structural basis for binding multiple ligands by the common cytokine receptor gamma-chain. J Biol Chem 2002, 277:12047-12052
49. Giri JG, Kumaki S, Ahdieh M, Fried JT, Loomis A, Shanebeck K, DuBoise R, Cosman D, Park LS, Anderson DM: Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 1995, 14:3654-3663
50. Chen E, Gadina M, Chen M, O'Shea JJ: Advances in cytokine signaling: the role of Jak and STATs. Transplant Proc 1999, 31:1482-1487
51. Gadina M, Sudarshan C, Visconti R, Zhou YJ, Ghu M, Neel BG, O'Shea JJ: The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common cytokine chain-using cytokines. J Biol Chem 2000, 275:26959-26966
52. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I: Development and function of T cells in mice rendered interleukin-15-deficient by gene targeting. Nature 1991, 352:621-624
53. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrrier K, Segder L, Willis CR, Brasel K, Morrissey PJ, Stocking K, Schuh JC, Joyce S, Peschon J: Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000, 191:771-780
54. Lodolce JP, Boone DL, Chai S, Swain RE, Dussapoulos T, Trettin S, Ma A: IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676
55. Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohn mạngh GA, Klein HG, FM M: Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biology 2002, 3:35:31-35:17
56. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer A, van Deursen J, Sangster M, Bunting KD, Grosveld GC, Ihle JN: Stats is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999, 10:249-259
57. Hoffmeyer A, Piekarz R, Moriggl R, Ihle JN: Gadd45gamma is dispensable for normal mouse development and T-cell proliferation. Mol Cell Biol 2001, 21:3137-3143
58. Li C, Wong W Hung: Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001, 2(8):Research0032

Publish with BioMed Central and every scientist can read your work free of charge
"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime.”
Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with BMC and your research papers will be:
• available free of charge to the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours - you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/editorial@biomedcentral.com